SLFN5 and central nervous system cancer: (18) conducted a study demonstrating that SLFN5 expression promotes the motility and invasiveness of glioblastoma multiforme (GBM) cells, and high levels of SLFN5 expression are associated with lower survival rates in high-grade gliomas and GBM patients.